Targeting EGFR/HER2/HER3 with a Three-in-One Aptamer-siRNA Chimera Confers Superior Activity against HER2+ Breast Cancer
HER family members are interdependent and functionally compensatory. Simultaneously targeting EGFR/HER2/HER3 by antibody combinations has demonstrated superior treatment efficacy over targeting one HER receptor. However, antibody combinations have their limitations, with high immunogenicity and high...
Saved in:
Main Authors: | Xiaolin Yu (Author), Sharad Ghamande (Author), Haitao Liu (Author), Lu Xue (Author), Shuhua Zhao (Author), Wenxi Tan (Author), Lijing Zhao (Author), Shou-Ching Tang (Author), Daqing Wu (Author), Hasan Korkaya (Author), Nita J. Maihle (Author), Hong Yan Liu (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2018-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Improved Aptamers for the Diagnosis and Potential Treatment of HER2-Positive Cancer
by: Marlies Gijs, et al.
Published: (2016) -
Identification of potential therapeutic dual inhibitors of EGFR/HER2 in breast cancer
by: Megha Jethwa, et al.
Published: (2024) -
The status of HER2 in colorectal carcinoma and the relation of HER2 with prognostic parameters and MSI
by: Ismail Saygin, et al.
Published: (2022) -
Brenda, Her School and Her Club
by: Reed, Helen Leah, 1860?-1926; Smith, Jessie Willcox, 1863-1935 [Illustrator] -
Benzo[g]quinazolin-based scaffold derivatives as dual EGFR/HER2 inhibitors
by: Mostafa M. Ghorab, et al.
Published: (2018)